Cantex and Headlamp Health are teaming up to accelerate the development of azeliragon for severe depression and fatigue in MS ...
Anti-CD20 therapies and S1P receptor modulators seem to be equally effective for most people with late-onset MS, a real-world ...
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in ...
Cantex Pharmaceuticals, Inc. ("Cantex"), a clinical-stage biopharmaceutical company, and Headlamp Health ("Headlamp"), an AI-native precision neuropsychiatry company, today announced a collaboration ...
Two experimental drug molecules promoted myelin repair in MS disease models, pointing toward a possible future route for ...
Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.
Thousands of Canadians will come together this May 31st for MS Canada’s annual MS Walk, a powerful, community-driven event dedicated to supporting people affected by multiple sclerosis (MS). With over ...
The US FDA has approved ocrelizumab (Ocrevus, Genentech) intravenous infusion for children aged 10 years and older with relapsing-remitting multiple sclerosis (RRMS) who weigh at least 55 lbs (25 kg), ...
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results